lercanidipine

Key facts

Drug.verifiedrevid

408573138

Drug.IUPAC_name

(RS)-2[(3,3-Diphenylpropyl)(methyl)amino]-1,1-dimethylethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Drug.image

Lercanidipine.svg

Drug.image_class

skin-invert-image

Drug.width

200

Drug.tradename

Zanidip, Leridip

Drug.pregnancy_category

C (no data in humans)

Drug.legal_status

Rx-only

Drug.routes_of_administration

Oral

Drug.bioavailability

~10% (due to first-pass effect)

Drug.protein_bound

>98%

Drug.metabolism

Mainly CYP3A4

Drug.elimination_half life

8–10 hours

Drug.duration_of_action

≥ 24 hours

Drug.excretion

Urine (50%)

Drug.CAS_number

100427-26-7

Drug.CAS_supplemental

(HCl)

Drug.ATC_prefix

C08

via Wikipedia infobox

Chemical data

Formula

C36H41N3O6

Molecular weight

611.7 g/mol

IUPAC name

5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC

InChIKey

ZDXUKAKRHYTAKV-UHFFFAOYSA-N

XLogP

6.9

Polar surface area

114 Ų

H-bond donors

1

H-bond acceptors

8

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Phase 3

Molecule type

Small molecule

Indications

cardiovascular disease, hypertension, essential hypertension

via ChEMBL · EBI

• Lercanidipine in the Management of Hypertension: An Update.Journal of pharmacology & pharmacotherapeutics · 2017
• Lercanidipine in hypertension.Vascular health and risk management · 2005
• Lercanidipine's Antioxidative Effect Prevents Noise-Induced Hearing Loss.Antioxidants (Basel, Switzerland) · 2024
• Lercanidipine in the treatment of hypertension.The Annals of pharmacotherapy · 2007
• Lercanidipine: a review of its use in hypertension.Drugs · 2000

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

611.299536

Has use

medication

via Wikidata · CC0